Products

CAS: 134678 -17-4 Lamivudine Powder

China CAS: 134678-17-4 Lamivudine Powder, Find details about China Lamivudine, Lamivudine Powder from CAS: 134678-17-4 Lamivudine Powder

Model NO.
HNB-Lamivudine
Product Name
Lamivudine
CAS
134678-17-4
Molecular Weight
229.256
Molecular Formula
C8h11n3o3s
Density
1.7±0.1 g/cm3
Assay
HPLC99%
Sample
10g Available
Factory Supply
Yes
Usage
Animal Pharmaceuticals
Shelf Life
2 Years Proper Storage
Certificate
GMP/ISO9001
Packing
Carton Box or Drum
Payment
Tt/Western Union
Trademark
HNB
Transport Package
Carton Box
Specification
HPLC 99%
Origin
China
HS Code
3006920000
Model NO.
HNB-Lamivudine
Product Name
Lamivudine
CAS
134678-17-4
Molecular Weight
229.256
Molecular Formula
C8h11n3o3s
Density
1.7±0.1 g/cm3
Assay
HPLC99%
Sample
10g Available
Factory Supply
Yes
Usage
Animal Pharmaceuticals
Shelf Life
2 Years Proper Storage
Certificate
GMP/ISO9001
Packing
Carton Box or Drum
Payment
Tt/Western Union
Trademark
HNB
Transport Package
Carton Box
Specification
HPLC 99%
Origin
China
HS Code
3006920000
CAS: 134678-17-4 Lamivudine Powder
Cas: 134678-17-4 Lamivudine powder
 
product nameLamivudine
cas number134678-17-4
apperanceWhite powder
Density1.7±0.1 g/cm3
MFC8H11N3O3S
MW229.256

CAS: 134678-17-4 Lamivudine Powder
Lamivudine, also known as 3-TC, is a nucleoside analogue and antiviral drug. It is a white or off-white crystalline powder. It is soluble in water and slightly soluble in methanol. It can synthesize and extend the viral DNA chain. There is a competitive inhibitory effect.
CAS: 134678-17-4 Lamivudine PowderIndications
Chronic hepatitis B caused by hepatitis B and hepatitis B virus replication.
[Patient's choice] 1. Suitable for treatment of chronic hepatitis B; according to the national viral hepatitis prevention and treatment plan, the diagnosis of chronic hepatitis B is not limited to gender, age 16 or older, and meets the following criteria. · HBeAg positive, HBV DNA positive (HBV DNA positive refers to dot blot method, not PCR positive, HBV DNA quantitative determination can be done if conditions permit. Where there is no condition to detect HBV DNA, HBeAg positive shall prevail). · HBeAg-negative, anti-HBe-positive, and HBV DNA-positive are also suitable for treatment in consideration of pre-C region mutations. · ALT is higher than normal and bilirubin is lower than 50μmol/L (3.0mg/dL). 2. Not suitable for treatment targets · Autoimmune liver disease. ·Inherited liver diseases: such as hepatolenticular degeneration, Wilson disease, hemochromatosis, alpha antitrypsin deficiency, etc. ·Bone marrow suppression: hemoglobin <10g/L, white blood cells <4x109/L, platelets <80x109/L (So far, lamivudine has not been found to have bone marrow suppression in clinical studies. For patients with bone marrow suppression tendency, strictly follow Doctor's order). · Have obvious heart, brain, nerve, mental illness and unstable diabetes. ·Pregnant women.
CAS: 134678-17-4 Lamivudine PowderCAS: 134678-17-4 Lamivudine PowderCAS: 134678-17-4 Lamivudine PowderCAS: 134678-17-4 Lamivudine PowderCAS: 134678-17-4 Lamivudine PowderCAS: 134678-17-4 Lamivudine PowderCAS: 134678-17-4 Lamivudine Powder
CAS: 134678-17-4 Lamivudine PowderCAS: 134678-17-4 Lamivudine Powder
 

You Might Also Like